Abstract: Radionuclide labelled somatostatin analogues have been widely used in the detection of neuro-endocrine tumors. Till now, most of somatostatin analogues only have high affinity to somatostatin receptor 2(SSTR2), further clinical applications was limitted. A new generation of somatostatin analogues such as 1,4,7,10-tetraazacyclodocecane-N,N',N",N'"-tetaraacetic acid-Nal3-octertide(DOTA-NOC) etc,binding to somatostatin receptors not only SSTR2 but other subtypes has been used mainly in preclinical study. In this review, we discussed these new somatostatin analogues, chelating agent, and their new labelled compounds, these new radionuclide labelled somatostatin analogues may hold great promise for the receptor-mediated tumor imaging and treatments.